| Therapeutic | Panitumumab |
| Target | EGFR/ERBB1/HER1 |
| Heavy Chain | QVQLQESGPGLVKPSETLSLTCTVSGGSVSSGDYYWTWIRQSPGKGLEWIGHIYYSGNTNYNPSLKSRLTISIDTSKTQFSLKLSSVTAADTAIYYCVRDRVTGAFDIWGQGTMVTVSS |
| Light Chain | DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYFCQHFDHLPLAFGGGTKVEIK |
| 100% seqID Fv Structure | 5sx4 [Fvs: HL, JI], 5sx5 [Fvs: HL, JK] |
| 99% seqID Fv Structure | None |
| 95-98% seqID Fv Structure | None |
| 100% seqID Structure | 5sx5 [Fvs: HL, JK] |
| 100% seqID Structure | 5sx4 [Fvs: HL, JI] |
Follow these links to our prediction tools:
| Format | Whole mAb |
| Isotype | G2 |
| Highest Clinical Trial (Feb '25) | Approved |
| Estimated Status (Feb '25) | Active |
| Recorded Developmental Technology | Abgenix XenoMouse |
| INN Year Proposed | 2004 |
| INN Year Recommended | 2005 |
| Companies Involved | Amgen, Grupo Espanol Multidisciplinario del Cancer Digestivo, Netherlands Cancer Institute, Novartis, Takeda, University of Texas M. D. Anderson Cancer Center, Wissenschaftlicher Service Pharma |
| Conditions Approved | Colorectal cancer |
| Conditions Active | Anal cancer, Bladder cancer, Breast cancer, Gastric cancer, Neuroendocrine tumours, Oesophageal cancer, Rectal cancer |
| Conditions Discontinued | Head and neck cancer, Malignant melanoma, Prostate cancer, Renal cell carcinoma, Solid tumours |
| Notes |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]
